UK's Latest Cancer Drug Cull Draws Renewed Calls For Reform
This article was originally published in Scrip
New cuts to publicly funded NHS oncology treatments announced in Britain have triggered fresh criticisms of the government's Cancer Drugs Fund and renewed calls for a system-wide overhaul of the way cancer drugs are commissioned in the country.
You may also be interested in...
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.